Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up)
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000053278
- Lead Sponsor
- Shionogi & Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 300000
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients under 18 years of age at the time of IM 2. Patients with dispending days of multiple anti-SARS-CoV-2 drugs in IM 3. Patients with a COVID-19 diagnosis within 3 months prior to IM 4. Patients who have been diagnosed with the same event as the post-COVID condition within 6 months before IM 5. Patients at risk of severe COVID-19
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Post-COVID conditions incidence from 2 to 3 months after the month of diagnosis of COVID-19
- Secondary Outcome Measures
Name Time Method